Limits...
Association between plasma fluorescent oxidation products and erectile dysfunction: A prospective study.

Yang S, Giovannucci E, Bracken B, Ho SM, Wu T - BMC Urol (2015)

Bottom Line: Existing epidemiological studies of the association between oxidative stress and erectile dysfunction (ED) are sparse and inconclusive, which is likely due to cross-sectional design and small sample size.We did not find an independent association between FlOP_360, FlOP_320, FlOP_400 and risk of ED in the multivariable adjusted model (Tertile 3 vs. tertile 1: odds ratio [OR] = 0.90, 95% confidence interval [CI] = 0.61-1.34, P(trend) = 0.54 for FlOP_360; OR = 0.73, 95% CI = 0.49-1.07, P(trend) = 0.27 for FlOP_320; and OR = 0.98, 95% CI = 0.66-1.45, P(trend) = 0.72 for FlOP_400).Plasma FlOPs were not associated with the risk of ED, suggesting oxidative stress may not be an independent risk factor for ED.

View Article: PubMed Central - PubMed

Affiliation: Division of Epidemiology and Biostatistics, Department of Environmental Health, University of Cincinnati Medical Center, Kettering Complex, 3223 Eden Ave, Cincinnati, OH, USA, 45267-0056. ysm992511@sina.com.

ABSTRACT

Background: Existing epidemiological studies of the association between oxidative stress and erectile dysfunction (ED) are sparse and inconclusive, which is likely due to cross-sectional design and small sample size. Therefore, we investigated the association between biomarkers of oxidative stress and ED in prospective setting among a relatively large sample size of men.

Methods: We conducted the prospective study among 917 men ages between 47 and 80 years at the time of blood draw, which is a part of nested prospective case-control study of prostate cancer in the Health Professionals Follow-up Study. Plasma fluorescent oxidation products (FlOPs), a global biomarker for oxidative stress, were measured at three excitation/emission wavelengths (360/420 nm named as FlOP_360; 320/420 nm named as FlOP_320 and 400/475 nm named as FlOP_400).

Results: Approximately 35% of men developed ED during follow-up. We did not find an independent association between FlOP_360, FlOP_320, FlOP_400 and risk of ED in the multivariable adjusted model (Tertile 3 vs. tertile 1: odds ratio [OR] = 0.90, 95% confidence interval [CI] = 0.61-1.34, P(trend) = 0.54 for FlOP_360; OR = 0.73, 95% CI = 0.49-1.07, P(trend) = 0.27 for FlOP_320; and OR = 0.98, 95% CI = 0.66-1.45, P(trend) = 0.72 for FlOP_400). Further analysis of the association between FlOPs and ED in the fasting samples or controls only (free of prostate cancer incidence) did not change the results appreciably.

Conclusions: Plasma FlOPs were not associated with the risk of ED, suggesting oxidative stress may not be an independent risk factor for ED.

No MeSH data available.


Related in: MedlinePlus

Flowchart of the participants excluded from the nested prospective case–control study of prostate cancer in the Health Professional Follow-up Study 1993–2001
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4536733&req=5

Fig1: Flowchart of the participants excluded from the nested prospective case–control study of prostate cancer in the Health Professional Follow-up Study 1993–2001

Mentions: The Health Professionals Follow-up Study (HPFS) initiated in 1986 is an ongoing prospective study of 51,529 men. Between 1993 and 1995, blood collection kits were sent to participants and 18,140 men returned specimens on ice by using an overnight courier. All returned blood samples were processed within 36 h after blood draw and stored in liquid nitrogen freezers. Based on the participants who donated blood samples, a 1:1 matched nested prospective case–control study of prostate cancer was performed from the time of blood draw [17]. All participants were free of diagnosed cardiovascular diseases and cancers at the time of blood draw. After excluding the ineligible participants (Fig. 1), we finally included 917 men ages between 47 and 80 years (median = 62 years) at the time of blood draw in the prospective study. Among 917 men, 457 and 460 men were subsequent incident prostate cancer cases and controls, respectively. Written informed consent was obtained from all participants. This investigation was approved by Institutional Review Board of the Brigham and Women’s Hospital, the Harvard School of Public Health and the University of Cincinnati.Fig. 1


Association between plasma fluorescent oxidation products and erectile dysfunction: A prospective study.

Yang S, Giovannucci E, Bracken B, Ho SM, Wu T - BMC Urol (2015)

Flowchart of the participants excluded from the nested prospective case–control study of prostate cancer in the Health Professional Follow-up Study 1993–2001
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4536733&req=5

Fig1: Flowchart of the participants excluded from the nested prospective case–control study of prostate cancer in the Health Professional Follow-up Study 1993–2001
Mentions: The Health Professionals Follow-up Study (HPFS) initiated in 1986 is an ongoing prospective study of 51,529 men. Between 1993 and 1995, blood collection kits were sent to participants and 18,140 men returned specimens on ice by using an overnight courier. All returned blood samples were processed within 36 h after blood draw and stored in liquid nitrogen freezers. Based on the participants who donated blood samples, a 1:1 matched nested prospective case–control study of prostate cancer was performed from the time of blood draw [17]. All participants were free of diagnosed cardiovascular diseases and cancers at the time of blood draw. After excluding the ineligible participants (Fig. 1), we finally included 917 men ages between 47 and 80 years (median = 62 years) at the time of blood draw in the prospective study. Among 917 men, 457 and 460 men were subsequent incident prostate cancer cases and controls, respectively. Written informed consent was obtained from all participants. This investigation was approved by Institutional Review Board of the Brigham and Women’s Hospital, the Harvard School of Public Health and the University of Cincinnati.Fig. 1

Bottom Line: Existing epidemiological studies of the association between oxidative stress and erectile dysfunction (ED) are sparse and inconclusive, which is likely due to cross-sectional design and small sample size.We did not find an independent association between FlOP_360, FlOP_320, FlOP_400 and risk of ED in the multivariable adjusted model (Tertile 3 vs. tertile 1: odds ratio [OR] = 0.90, 95% confidence interval [CI] = 0.61-1.34, P(trend) = 0.54 for FlOP_360; OR = 0.73, 95% CI = 0.49-1.07, P(trend) = 0.27 for FlOP_320; and OR = 0.98, 95% CI = 0.66-1.45, P(trend) = 0.72 for FlOP_400).Plasma FlOPs were not associated with the risk of ED, suggesting oxidative stress may not be an independent risk factor for ED.

View Article: PubMed Central - PubMed

Affiliation: Division of Epidemiology and Biostatistics, Department of Environmental Health, University of Cincinnati Medical Center, Kettering Complex, 3223 Eden Ave, Cincinnati, OH, USA, 45267-0056. ysm992511@sina.com.

ABSTRACT

Background: Existing epidemiological studies of the association between oxidative stress and erectile dysfunction (ED) are sparse and inconclusive, which is likely due to cross-sectional design and small sample size. Therefore, we investigated the association between biomarkers of oxidative stress and ED in prospective setting among a relatively large sample size of men.

Methods: We conducted the prospective study among 917 men ages between 47 and 80 years at the time of blood draw, which is a part of nested prospective case-control study of prostate cancer in the Health Professionals Follow-up Study. Plasma fluorescent oxidation products (FlOPs), a global biomarker for oxidative stress, were measured at three excitation/emission wavelengths (360/420 nm named as FlOP_360; 320/420 nm named as FlOP_320 and 400/475 nm named as FlOP_400).

Results: Approximately 35% of men developed ED during follow-up. We did not find an independent association between FlOP_360, FlOP_320, FlOP_400 and risk of ED in the multivariable adjusted model (Tertile 3 vs. tertile 1: odds ratio [OR] = 0.90, 95% confidence interval [CI] = 0.61-1.34, P(trend) = 0.54 for FlOP_360; OR = 0.73, 95% CI = 0.49-1.07, P(trend) = 0.27 for FlOP_320; and OR = 0.98, 95% CI = 0.66-1.45, P(trend) = 0.72 for FlOP_400). Further analysis of the association between FlOPs and ED in the fasting samples or controls only (free of prostate cancer incidence) did not change the results appreciably.

Conclusions: Plasma FlOPs were not associated with the risk of ED, suggesting oxidative stress may not be an independent risk factor for ED.

No MeSH data available.


Related in: MedlinePlus